From James Van Der Beek spreading awareness about colorectal cancer at a younger age to Gerry Connolly’s recent esophageal ...

EMA approves Dupixent to treat eosinophilic esophagitis in children as young as one year: Paris Thursday, November 7, 2024, 14:00 Hrs [IST] The European Medicines Agency has appro ...

Study of real-world outcomes confirms a new way of treating esophageal cancer Current clinical trials consider ... Boosting ...

Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitisApproval based on phase 3 data showing ...

Paris: Sanofi has announced that the European Medicines Agency has approved Dupixent (dupilumab) to treat eosinophilic ...

Approval based on Phase 3 data showing significantly more children aged 1 to 11 years on Dupixent achieved histological disease remission at 16 ...

A study aims to determine whether restoring a healthy intestinal environment can make drugs used in the treatment of ...

Parents of these children have often relied on restrictive diets that do not specifically ... half of all children in the EU with eosinophilic esophagitis remain uncontrolled despite existing ...

“Young children with eosinophilic esophagitis are at the beginning of ... “Parents of these children have often relied on restrictive diets that do not specifically address the disease and ...

“Parents of these children have often relied on restrictive diets that do not specifically ... “Eosinophilic esophagitis presents a unique challenge in young children, who struggle with ...

Approval based on phase 3 data showing significantly more children aged one to 11 years on Dupixent achieved histological disease remission at 16 weeks compared to placebo, which was sustained up ...